Lexaria Bioscience (LEXX) Current Deferred Revenue (2016 - 2024)
Lexaria Bioscience's (LEXX) quarterly Current Deferred Revenue came in at $4963.0 in Q3 2024, up 16.09% quarter-over-quarter from $4275.0 in Q1 2023.
Lexaria Bioscience (LEXX) Current Deferred Revenue (2016 - 2024) Analysis & Trends
Lexaria Bioscience has disclosed Current Deferred Revenue across 6 years of filings, most recently posting $4963.0 for Q3 2024.
- Current Deferred Revenue for Q3 2024 came in at $4963.0, changed N/A year-over-year; the trailing twelve-month figure through Aug 2024 was $4963.0 (changed N/A YoY), and the FY2024 annual result was $4963.0, changed N/A from the prior year.
- Current Deferred Revenue came in at $4963.0 for Q3 2024 at Lexaria Bioscience, up from $4275.0 in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $44255.0 in Q3 2020 to a low of $1000.0 in Q1 2021.
- The 4-year median for Current Deferred Revenue is $5606.5 (2020), against an average of $16040.5.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Lexaria Bioscience | 7.17 Mn | 1.65 Mn | 20,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Aug 31, 2024 | 4,963.00 |
| Feb 28, 2023 | 4,275.00 |
| Feb 28, 2021 | 1,000.00 |
| Nov 30, 2020 | 35,500.00 |
| Aug 31, 2020 | 44,255.00 |
| May 31, 2020 | 6,250.00 |
| Nov 30, 2017 | 10,833.00 |
| Aug 31, 2017 | 17,083.00 |
| May 31, 2017 | 19,600.00 |
| Feb 28, 2017 | 24,969.00 |
| Nov 30, 2016 | 21,150.00 |
| Aug 31, 2016 | 12,500.00 |
| May 31, 2016 | 8,819.00 |